methyl 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxylate | 1190837-06-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxylate
• 英文别名: methyl 4-(4-nitro-2-fluorophenoxy)-7-methoxyquinoline-6-carboxylate
• CAS: 1190837-06-9
• 化学式: C₁₈H₁₃FN₂O₆
• 分子量: 372.309
• InChiKey: PTBFYTYXPOMQTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxylate 在 ammonium hydroxide 、 铁粉 、 氯化铵 作用下， 以 甲醇 、 乙醇 、 水 、 二甲基亚砜 为溶剂， 生成 4-(4-amino-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide
  参考文献：
  名称：

  OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。

  公开号：

  EP4011885A1
• 作为产物：
  描述：

  4-氯-7-甲氧基喹啉-6-羧酸甲酯 、 2-氟-4-硝基苯酚 在 二异丙胺 作用下， 生成 methyl 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxylate
  参考文献：
  名称：

  OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。

  公开号：

  EP4011885A1

文献信息

• ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF
  申请人：Suda Yoshimitsu

  公开号：US20110034439A1

  公开（公告）日：2011-02-10

  To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. The invention provides an acylthiourea compound represented by formula (I): (wherein each of R 1 and R 2 , which may be the same or different, represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-10 cycloalkyl group, an optionally substituted C 6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 1 and R 2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R 3 represents a C 1-6 alkyl group; and each of R 4 , R 5 , and R 6 , which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 5 and R 6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof.

  提供一种抗肿瘤剂，其表现出优异的c-Met抑制作用，并通过选择性地影响c-Met特异表达的肿瘤细胞来减轻副作用。本发明提供一种由式(I)表示的酰基硫脲化合物：（其中，R1和R2中的每一个，可以相同也可以不同，表示氢原子，可选取代的C1-6烷基，可选取代的C3-10环烷基，可选取代的C6-14芳香烃基，或可选取代的饱和或不饱和杂环基，或R1和R2可以与它们所附着的氮原子一起形成一个可选取代的含氮杂环环；R3表示C1-6烷基；R4、R5和R6中的每一个，可以相同也可以不同，表示氢原子，卤素原子，可选取代的C1-6烷基，C1-6烷氧基，C1-6烷基氨基，可选取代的芳香烃基，或可选取代的饱和或不饱和杂环基，或R5和R6可以与它们所附着的苯环一起形成一个环）。或其盐。
• ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2287155A1

  公开（公告）日：2011-02-23

  To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. The invention provides an acylthiourea compound represented by formula (I): (wherein each of R1 and R2, which may be the same or different, represents a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R3 represents a C1-6 alkyl group; and each of R4, R5, and R6, which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof.

  提供一种抗肿瘤药，该抗肿瘤药对特异性表达 c-Met 的肿瘤细胞具有选择性影响，从而显示出卓越的 c-Met 抑制作用并减轻副作用。 本发明提供了一种由式（I）代表的酰基硫脲化合物： (其中 R1 和 R2（可以相同或不同）各自代表氢原子、任选取代的 C1-6 烷基、任选取代的 C3-10 环烷基、任选取代的 C6-14 芳烃基团或任选取代的饱和或不饱和杂环基团，或 R1 和 R2 可与所连接的氮原子一起形成任选取代的含氮杂环；R3代表C1-6烷基；R4、R5和R6（它们可以彼此相同或不同）分别代表氢原子、卤素原子、任选取代的C1-6烷基、C1-6烷氧基、C1-6烷氨基、任选取代的芳香烃基团或任选取代的饱和或不饱和杂环基团，或R5和R6可与它们所连接的苯基环一起形成环）或其盐。
• US8304427B2
  申请人：——

  公开号：US8304427B2

  公开（公告）日：2012-11-06
• [EN] OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉ D'OXO-PYRIDINE À CYCLE CONDENSÉ ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT<br/>[KO] 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물
  申请人：WELLMARKER BIO CO LTD

  公开号：WO2021025407A1

  公开（公告）日：2021-02-11

  본 발명에 따른 화학식 1로 표시되는 옥소-피리딘 융합고리 유도체 화합물 또는 이의 약학적으로 허용가능한 염은 RON의 활성을 효과적으로 억제하며, RON이 활성화되어 있는 암세포주의 세포 성장을 효과적으로 저해할 뿐만 아니라, 상기 암세포주를 효과적으로 사멸시킬 수 있다. 따라서, 본 발명에 따른 화학식 1로 표시되는 옥소-피리딘 융합고리 유도체 화합물 또는 이의 약학적으로 허용가능한 염은 단백질 키나제 활성과 관련된 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
• OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Wellmarker Bio Co., Ltd.

  公开号：EP4011885A1

  公开（公告）日：2022-06-15

  An oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can be advantageously used for preventing or treating a disease associated with protein kinase activity.

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。